AUROBINDO PHARMA LTD vs MANIPAL HEALTH ENTERPRI L

A side-by-side comparison of AUROBINDO PHARMA LTD (AUROPHARMA) and MANIPAL HEALTH ENTERPRI L (MANIPALHOS) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, AUROBINDO PHARMA LTD leads AUROPHARMA vs MANIPALHOS on 9 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation40
  • Profitability13
  • Growth02
  • Size & financial health40
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

AUROPHARMA takes 4/4

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

27.51
P/E ratio
52.05
2.39
P/B ratio
5.81
0.24%
Dividend yield
0.00%
₹60.34
EPS
₹13.89

Profitability

MANIPALHOS takes 3/4

How efficiently each company turns capital and sales into profit. Higher is better.

10.10%
Return on equity
11.80%
13.00%
Return on capital
12.00%
20.00%
EBITDA margin
27.00%
10.41%
Net margin
17.24%

Growth

MANIPALHOS takes 2/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

10.63%
Revenue CAGR (3Y)
63.48%
22.02%
Profit CAGR (3Y)
67.79%

Size & financial health

AUROPHARMA takes 4/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹96,414 Cr
Market cap
₹95,990 Cr
₹33,653 Cr
Revenue
₹3,104 Cr
₹3,503 Cr
Net profit
₹535 Cr
0.19
Debt / equity
0.48
AUROBINDO PHARMA LTD
  • ["Stock is trading at 2.53 times its book value", "The company has delivered a poor sales growth of 6.32% over past five years.", "Company has a low return on equity of 10.8% over last 3 years.", "Company might be capitalizing the interest cost"]
MANIPAL HEALTH ENTERPRI L
  • + ["Company has delivered good profit growth of 26.0% CAGR over last 5 years"]
  • ["Company has a low return on equity of 10.2% over last 3 years."]
AUROBINDO PHARMA LTD full analysis MANIPAL HEALTH ENTERPRI L full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.